Clinical Trials Directory

Trials / Completed

CompletedNCT05550129

Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants

A Phase I, Open-label Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

The primary objectives of this study are to evaluate the effect of AMG 510 on the pharmacokinetics (PK) of metformin in healthy participants and to evaluate the effect of metformin on the PK of AMG 510 in healthy participants.

Conditions

Interventions

TypeNameDescription
DRUGAMG 510Oral tablet
DRUGMetforminOral tablet

Timeline

Start date
2019-11-13
Primary completion
2019-11-25
Completion
2019-11-25
First posted
2022-09-22
Last updated
2025-03-05

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05550129. Inclusion in this directory is not an endorsement.

Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants (NCT05550129) · Clinical Trials Directory